FDMT
4D Molecular Therapeutics Inc.
$7.67
+$0.27(+3.65%)
91
Overall
--
Value
91
Tech
--
Quality
Market Cap
$312.44M
Volume
1.10M
52W Range
$2.24 - $11.77
Target Price
$28.78
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $13.6M | $18.0M | $3.1M | $20.7M | $37.0K | ||
| Total Revenue | $13.6M | $18.0M | $3.1M | $20.7M | $37.0K | ||
| GROSS PROFIT | |||||||
| Gross Profit | $13.6M | $18.0M | $3.1M | $20.7M | $37.0K | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $70.3M | $89.4M | $113.2M | $133.6M | $187.9M | ||
| Research & Development | $53.0M | $61.4M | $80.3M | $97.1M | $141.3M | ||
| Research Expense | $53.0M | $61.4M | $80.3M | $97.1M | $141.3M | ||
| Selling, General & Administrative | $17.2M | $28.0M | $32.9M | $36.5M | $46.6M | ||
| General & Administrative Expenses | $17.2M | $28.0M | $32.9M | $36.5M | $46.6M | ||
| Salaries & Wages | -- | -- | -- | $19.7M | $26.1M | ||
| Depreciation & Amortization | $1.4M | $1.5M | $2.4M | $4.4M | $4.8M | ||
| Depreciation & Amortization | $1.4M | $1.5M | $2.4M | $4.4M | $4.8M | ||
| Other Operating Expenses | $-1.7M | $-2.2M | $-2.7M | $-3.6M | $-2.9M | ||
| OPERATING INCOME | |||||||
| Operating income | $-56.7M | $-71.3M | $-110.0M | $-112.9M | $-187.8M | ||
| EBITDA | $-55.2M | $-68.3M | $-106.2M | $-95.1M | $-154.2M | ||
| NON-OPERATING ITEMS | |||||||
| Intinc | $152.0K | $137.0K | $2.6M | $12.2M | $27.1M | ||
| Net Non-Operating Interest Income/Expense | $152.0K | $137.0K | $2.6M | $12.2M | $27.1M | ||
| Other Income/Expense | $181.0K | $121.0K | $-35.0K | $181.0K | $77.0K | ||
| Other Special Charges | $-181.0K | $-121.0K | $-35.0K | $-181.0K | $-77.0K | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-56.7M | $-71.3M | $-110.0M | $-100.8M | $-160.9M | ||
| Pre-Tax Income | $-56.7M | $-71.3M | $-107.5M | $-100.8M | $-160.9M | ||
| NET INCOME | |||||||
| Net Income | $-56.7M | $-71.3M | $-107.5M | $-100.8M | $-160.9M | ||
| Net Income (Continuing Operations) | $-56.7M | $-71.3M | $-107.5M | $-100.8M | $-160.9M | ||
| Net Income (Discontinued Operations) | $-56.7M | $-71.3M | $-107.5M | $-100.8M | $-160.9M | ||
| Net Income (Common Stockholders) | $-56.7M | $-71.3M | $-107.5M | $-100.8M | $-160.9M | ||
| Normalized Income | -- | -- | -- | -- | $-159.3M | ||
| TOTALS | |||||||
| Total Expenses | $70.3M | $89.4M | $113.2M | $133.6M | $187.9M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $6.4M | $27.7M | $32.4M | $39.1M | $53.9M | ||
| Average Shares Outstanding (Diluted) | $6.4M | -- | $32.4M | $39.1M | $53.9M | ||
| Shares Outstanding | $26.7M | $32.2M | $33.2M | $49.8M | $55.7M | ||
| Basic EPS | $-8.82 | $-2.57 | $-3.32 | $-2.58 | $-2.98 | ||
| Basic EPS (Continuing Operations) | $-8.82 | $-2.57 | $-3.32 | $-2.58 | $-2.98 | ||
| Diluted EPS | $-8.82 | $-2.57 | $-3.32 | $-2.58 | $-2.98 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-3.32 | $-2.58 | $-2.98 | ||
| OTHER METRICS | |||||||
| Other Gand A | $17.2M | $28.0M | $32.9M | $36.5M | $46.6M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FDMT | $7.67 | +3.6% | 1.10M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get 4D Molecular Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW